Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 17:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.
May 06, 2025 07:03 ET | Source: Pasithea

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.
May 05, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
April 29, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics completes Cohort 6 enrollment and dosing in Phase 1 PAS-004 trial for MAPK-driven advanced cancers; full enrollment by 2025.
April 24, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.
April 16, 2025 04:22 ET | Source: Research and Markets

Thyroid Cancer Drugs Industry and Companies Analysis Report 2025: A $2.2 Billion Landscape by 2029

Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Market Report 2025" has been added to ResearchAndMarkets.com's offering. The thyroid cancer drugs market has demonstrated...
April 10, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
March 21, 2025 16:30 ET | Source: Immuneering Corporation

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award
March 20, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Next Page keyboard_arrow_right